SAT0463 Incidence of Herpes Zoster Infections in Juvenile Idiopathic Arthritis Patients – Experience of the Biker Registry
Background An increased risk of herpes zoster among patients with juvenile idiopathic arthritis (JIA), especially with exposure to immunosuppressant medications and biologics have been described. Objectives We determined incidence rates of herpes zoster and medication among children with JIA. Method...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2013-06, Vol.72 (Suppl 3), p.A738 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Suppl 3 |
| container_start_page | A738 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 72 |
| creator | Horneff, G. Nimmrich, S. |
| description | Background An increased risk of herpes zoster among patients with juvenile idiopathic arthritis (JIA), especially with exposure to immunosuppressant medications and biologics have been described. Objectives We determined incidence rates of herpes zoster and medication among children with JIA. Methods Courses of treatments documented in the German Biologics Register (BiKeR) were analyzed to identify patients with herpes zoster and calculated crude infection rates (IR). Incidence ratio (IRR) was compared to published rates of 1.1/1000 person years(ref.). Demographics and exposure to corticosteroids, immunosuppressive drugs and biologics were analyzed. Results The JIA cohort included 3,042 patients with 5,407 person-years of follow-up; 1,628 have used corticosteroids, 2,930 have used methotrexate, 299 azathioprine, 192 cyclosportine A, 1685 etanercept, 299 adalimumab and 48 tocilizumab. In total 18 herpes zoster events have been documented (6/1000 patients [3.2-8.7]; 3.3/1000 patient years [2.1-5.3]). Thus the incidence rate was higher than expected (p |
| doi_str_mv | 10.1136/annrheumdis-2013-eular.2187 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777913000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008752641</sourcerecordid><originalsourceid>FETCH-LOGICAL-b2230-2e1b35a8cd63a9924c9a83b3eb5b8437ee01d4e161c0e95f9d1c5ffece9e039d3</originalsourceid><addsrcrecordid>eNqVkM9O3DAQxq2KSl22vIMlzgE7TpxYnJbVwqYCWpY_Qr1YjjNhvX-c1HYquFRceALekCdpttuiXjmNZvR938z8ENqn5IBSxg-VtW4O3boyPooJZRF0K-UOYppnH9CAJjzvx5zsoAEhhEWJ4NkntOv9om9JTvMB-nU1uiYJZ69Pz4XVpgKrATc1noJrwePvjQ_gcGFr0ME01mNj8ZfuJ1izAlxUpmlVmBuNRy7MnQnG428qGLDB49enFzx5aMGZf6FhDvjYLPvAGdwbH9zjZ_SxVisPe3_rEN2cTK7H0-js62kxHp1FZRwzEsVAS5aqXFecKSHiRAuVs5JBmZZ5wjIAQqsEKKeagEhrUVGd1v3NIIAwUbEh2t_mtq750YEPctF0zvYrJc2yTFC2ATRER1uVdo33DmrZOrNW7lFSIjfA5X_A5Qa4_ANcboD37mjr7j-DhzerckvJM5al8uJ2LNPL2R2bnU_lZa_nW325Xrxr0W-vWp66</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777913000</pqid></control><display><type>article</type><title>SAT0463 Incidence of Herpes Zoster Infections in Juvenile Idiopathic Arthritis Patients – Experience of the Biker Registry</title><source>BMJ Journals - NESLi2</source><creator>Horneff, G. ; Nimmrich, S.</creator><creatorcontrib>Horneff, G. ; Nimmrich, S.</creatorcontrib><description>Background An increased risk of herpes zoster among patients with juvenile idiopathic arthritis (JIA), especially with exposure to immunosuppressant medications and biologics have been described. Objectives We determined incidence rates of herpes zoster and medication among children with JIA. Methods Courses of treatments documented in the German Biologics Register (BiKeR) were analyzed to identify patients with herpes zoster and calculated crude infection rates (IR). Incidence ratio (IRR) was compared to published rates of 1.1/1000 person years(ref.). Demographics and exposure to corticosteroids, immunosuppressive drugs and biologics were analyzed. Results The JIA cohort included 3,042 patients with 5,407 person-years of follow-up; 1,628 have used corticosteroids, 2,930 have used methotrexate, 299 azathioprine, 192 cyclosportine A, 1685 etanercept, 299 adalimumab and 48 tocilizumab. In total 18 herpes zoster events have been documented (6/1000 patients [3.2-8.7]; 3.3/1000 patient years [2.1-5.3]). Thus the incidence rate was higher than expected (p<0.001, IRR 2.97 [1.9-4.7]. In all patients the event resolved. One developed intercostal neuralgia. 1 had a recurrent herpes zoster. The occurrence of herpes zoster was significantly associated with the exposure to corticosteriods (100% of pts with zoster compared to 53% of who did not develop zoster; p<0.0001) and the duration of exposure to methotrexate (70±56 months vs. 36±33 months; p<0.01). There was no association to age or disease duration. Compared to patients exposed to methotrexate, the exposure to any of the biologics etanercept, adalimumab or tocilizumab seemed not to further increase the risk of zoster, while exposure to azathioprine did (table). Conclusions In JIA patients herpes zoster infection was found to be associated with treatment with corticosteroids and the duration of treatment with methotrexate. No association between treatment with biologics, etanercept, adalimumab or tocilizumab was found. References Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005 Aug;20(8):748-53. Acknowledgements This study would not have been possible without the collaboration of numerous German and Austrian pediatric rheumatologists, patients and their parents. The German Registry is supported by Abbott, Pfizer (Wyeth Pharma) and Roche, Germany Disclosure of Interest G. Horneff Grant/research support from: Pfizer, Abbott, Roche, S. Nimmrich: None Declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2013-eular.2187</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><ispartof>Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A738</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b2230-2e1b35a8cd63a9924c9a83b3eb5b8437ee01d4e161c0e95f9d1c5ffece9e039d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/72/Suppl_3/A738.1.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/72/Suppl_3/A738.1.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77569,77600</link.rule.ids></links><search><creatorcontrib>Horneff, G.</creatorcontrib><creatorcontrib>Nimmrich, S.</creatorcontrib><title>SAT0463 Incidence of Herpes Zoster Infections in Juvenile Idiopathic Arthritis Patients – Experience of the Biker Registry</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Background An increased risk of herpes zoster among patients with juvenile idiopathic arthritis (JIA), especially with exposure to immunosuppressant medications and biologics have been described. Objectives We determined incidence rates of herpes zoster and medication among children with JIA. Methods Courses of treatments documented in the German Biologics Register (BiKeR) were analyzed to identify patients with herpes zoster and calculated crude infection rates (IR). Incidence ratio (IRR) was compared to published rates of 1.1/1000 person years(ref.). Demographics and exposure to corticosteroids, immunosuppressive drugs and biologics were analyzed. Results The JIA cohort included 3,042 patients with 5,407 person-years of follow-up; 1,628 have used corticosteroids, 2,930 have used methotrexate, 299 azathioprine, 192 cyclosportine A, 1685 etanercept, 299 adalimumab and 48 tocilizumab. In total 18 herpes zoster events have been documented (6/1000 patients [3.2-8.7]; 3.3/1000 patient years [2.1-5.3]). Thus the incidence rate was higher than expected (p<0.001, IRR 2.97 [1.9-4.7]. In all patients the event resolved. One developed intercostal neuralgia. 1 had a recurrent herpes zoster. The occurrence of herpes zoster was significantly associated with the exposure to corticosteriods (100% of pts with zoster compared to 53% of who did not develop zoster; p<0.0001) and the duration of exposure to methotrexate (70±56 months vs. 36±33 months; p<0.01). There was no association to age or disease duration. Compared to patients exposed to methotrexate, the exposure to any of the biologics etanercept, adalimumab or tocilizumab seemed not to further increase the risk of zoster, while exposure to azathioprine did (table). Conclusions In JIA patients herpes zoster infection was found to be associated with treatment with corticosteroids and the duration of treatment with methotrexate. No association between treatment with biologics, etanercept, adalimumab or tocilizumab was found. References Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005 Aug;20(8):748-53. Acknowledgements This study would not have been possible without the collaboration of numerous German and Austrian pediatric rheumatologists, patients and their parents. The German Registry is supported by Abbott, Pfizer (Wyeth Pharma) and Roche, Germany Disclosure of Interest G. Horneff Grant/research support from: Pfizer, Abbott, Roche, S. Nimmrich: None Declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkM9O3DAQxq2KSl22vIMlzgE7TpxYnJbVwqYCWpY_Qr1YjjNhvX-c1HYquFRceALekCdpttuiXjmNZvR938z8ENqn5IBSxg-VtW4O3boyPooJZRF0K-UOYppnH9CAJjzvx5zsoAEhhEWJ4NkntOv9om9JTvMB-nU1uiYJZ69Pz4XVpgKrATc1noJrwePvjQ_gcGFr0ME01mNj8ZfuJ1izAlxUpmlVmBuNRy7MnQnG428qGLDB49enFzx5aMGZf6FhDvjYLPvAGdwbH9zjZ_SxVisPe3_rEN2cTK7H0-js62kxHp1FZRwzEsVAS5aqXFecKSHiRAuVs5JBmZZ5wjIAQqsEKKeagEhrUVGd1v3NIIAwUbEh2t_mtq750YEPctF0zvYrJc2yTFC2ATRER1uVdo33DmrZOrNW7lFSIjfA5X_A5Qa4_ANcboD37mjr7j-DhzerckvJM5al8uJ2LNPL2R2bnU_lZa_nW325Xrxr0W-vWp66</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Horneff, G.</creator><creator>Nimmrich, S.</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201306</creationdate><title>SAT0463 Incidence of Herpes Zoster Infections in Juvenile Idiopathic Arthritis Patients – Experience of the Biker Registry</title><author>Horneff, G. ; Nimmrich, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b2230-2e1b35a8cd63a9924c9a83b3eb5b8437ee01d4e161c0e95f9d1c5ffece9e039d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Horneff, G.</creatorcontrib><creatorcontrib>Nimmrich, S.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Horneff, G.</au><au>Nimmrich, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SAT0463 Incidence of Herpes Zoster Infections in Juvenile Idiopathic Arthritis Patients – Experience of the Biker Registry</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2013-06</date><risdate>2013</risdate><volume>72</volume><issue>Suppl 3</issue><spage>A738</spage><pages>A738-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background An increased risk of herpes zoster among patients with juvenile idiopathic arthritis (JIA), especially with exposure to immunosuppressant medications and biologics have been described. Objectives We determined incidence rates of herpes zoster and medication among children with JIA. Methods Courses of treatments documented in the German Biologics Register (BiKeR) were analyzed to identify patients with herpes zoster and calculated crude infection rates (IR). Incidence ratio (IRR) was compared to published rates of 1.1/1000 person years(ref.). Demographics and exposure to corticosteroids, immunosuppressive drugs and biologics were analyzed. Results The JIA cohort included 3,042 patients with 5,407 person-years of follow-up; 1,628 have used corticosteroids, 2,930 have used methotrexate, 299 azathioprine, 192 cyclosportine A, 1685 etanercept, 299 adalimumab and 48 tocilizumab. In total 18 herpes zoster events have been documented (6/1000 patients [3.2-8.7]; 3.3/1000 patient years [2.1-5.3]). Thus the incidence rate was higher than expected (p<0.001, IRR 2.97 [1.9-4.7]. In all patients the event resolved. One developed intercostal neuralgia. 1 had a recurrent herpes zoster. The occurrence of herpes zoster was significantly associated with the exposure to corticosteriods (100% of pts with zoster compared to 53% of who did not develop zoster; p<0.0001) and the duration of exposure to methotrexate (70±56 months vs. 36±33 months; p<0.01). There was no association to age or disease duration. Compared to patients exposed to methotrexate, the exposure to any of the biologics etanercept, adalimumab or tocilizumab seemed not to further increase the risk of zoster, while exposure to azathioprine did (table). Conclusions In JIA patients herpes zoster infection was found to be associated with treatment with corticosteroids and the duration of treatment with methotrexate. No association between treatment with biologics, etanercept, adalimumab or tocilizumab was found. References Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005 Aug;20(8):748-53. Acknowledgements This study would not have been possible without the collaboration of numerous German and Austrian pediatric rheumatologists, patients and their parents. The German Registry is supported by Abbott, Pfizer (Wyeth Pharma) and Roche, Germany Disclosure of Interest G. Horneff Grant/research support from: Pfizer, Abbott, Roche, S. Nimmrich: None Declared</abstract><cop>Kidlington</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><doi>10.1136/annrheumdis-2013-eular.2187</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A738 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_proquest_journals_1777913000 |
| source | BMJ Journals - NESLi2 |
| title | SAT0463 Incidence of Herpes Zoster Infections in Juvenile Idiopathic Arthritis Patients – Experience of the Biker Registry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T05%3A12%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SAT0463%E2%80%85Incidence%20of%20Herpes%20Zoster%20Infections%20in%20Juvenile%20Idiopathic%20Arthritis%20Patients%20%E2%80%93%20Experience%20of%20the%20Biker%20Registry&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Horneff,%20G.&rft.date=2013-06&rft.volume=72&rft.issue=Suppl%203&rft.spage=A738&rft.pages=A738-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2013-eular.2187&rft_dat=%3Cproquest_cross%3E4008752641%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777913000&rft_id=info:pmid/&rfr_iscdi=true |